Micron Technology
MU
NVIDIA
NVDA
Adobe
ADBE
Tesla
TSLA
Netflix
NFLX
US Stock MarketDetailed Quotes
BRTX Biorestorative Therapies
- 1.770
- +0.150+9.26%
Close Mar 14 16:00 ET
- 1.710
- -0.060-3.38%
Post 18:27 ET
12.25MMarket Cap-1.24P/E (TTM)
1.780High1.620Low57.72KVolume1.640Open1.620Pre Close98.94KTurnover1.34%Turnover RatioLossP/E (Static)6.92MShares2.55052wk High1.23P/B7.65MFloat Cap1.03052wk Low--Dividend TTM4.32MShs Float8.900Historical High--Div YieldTTM9.88%Amplitude1.030Historical Low1.714Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Biorestorative Therapies Stock Forum
Maxim Group analyst Michael Okunewitch maintains $Biorestorative Therapies (BRTX.US)$ with a buy rating, and adjusts the target price from $6 to $8.
BioRestorative's FDA clearance for their BRTX-100 IND in chronic cervical discogenic pain represents a significant clinical and strategic expansion that could substantially enhance the company's market position in regenerative medicine for spinal conditions.
This development is particularly noteworthy for three key reasons:
BRTX-100 becomes the first and only stem cell therapy cleared for evaluation in cervical degenerative disc disease, esta...
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
First-Ever Stem Cell Treatment for Neck Pain Gets FDA Green Light - What Makes BRTX-100 Revolutionary?
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
Thursday, 27th February at 9:45 am
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting –
– IND clearance expands Company's advanced clinical pipeline for BRTX-100 treatment of both chronic lower back and neck pain –
– Company to host webcasted conference call today...
They have conference call tomorrow 10:30 am est
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
Wednesday, 26th February at 8:15 pm
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ: BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, announced today that it has changed the time for its previously ...
taking a starter position here
No comment yet